179 related articles for article (PubMed ID: 12704389)
1. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells.
Cheok MH; Yang W; Pui CH; Downing JR; Cheng C; Naeve CW; Relling MV; Evans WE
Nat Genet; 2003 May; 34(1):85-90. PubMed ID: 12704389
[TBL] [Abstract][Full Text] [Related]
2.
Xu H; Zhao X; Bhojwani D; E S; Goodings C; Zhang H; Seibel NL; Yang W; Li C; Carroll WL; Evans WE; Yang JJ
Clin Cancer Res; 2020 Jan; 26(1):256-264. PubMed ID: 31573954
[TBL] [Abstract][Full Text] [Related]
3. Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia.
Bökkerink JP; Damen FJ; Hulscher MW; Bakker MA; De Abreu RA
Haematol Blood Transfus; 1990; 33():110-7. PubMed ID: 2323622
[No Abstract] [Full Text] [Related]
4. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
5. Resistance revealed in acute lymphoblastic leukemia.
Aster JC; DeAngelo DJ
Nat Med; 2013 Mar; 19(3):264-5. PubMed ID: 23467232
[No Abstract] [Full Text] [Related]
6. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Holleman A; Cheok MH; den Boer ML; Yang W; Veerman AJ; Kazemier KM; Pei D; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
N Engl J Med; 2004 Aug; 351(6):533-42. PubMed ID: 15295046
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
8. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE
Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191
[TBL] [Abstract][Full Text] [Related]
9. Benign intracranial hypertension in association with acute lymphoblastic leukemia.
Sastry J; Karandikar SS; English MW
Pediatr Hematol Oncol; 2003 Mar; 20(2):157-60. PubMed ID: 12554527
[No Abstract] [Full Text] [Related]
10. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
11. Connecting the dots using gene-expression profiles.
Gullans SR
N Engl J Med; 2006 Nov; 355(19):2042-4. PubMed ID: 17093257
[No Abstract] [Full Text] [Related]
12. Intracellular pharmacology and biochemistry of methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; Bökkerink JP; Trijbels JM; vd Heijden MA; De Abreu RA
Adv Exp Med Biol; 1994; 370():115-8. PubMed ID: 7660872
[No Abstract] [Full Text] [Related]
13. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Efferth T; Sauerbrey A; Steinbach D; Gebhart E; Drexler HG; Miyachi H; Chitambar CR; Becker CM; Zintl F; Humeny A
Int J Oncol; 2003 Aug; 23(2):509-17. PubMed ID: 12851703
[TBL] [Abstract][Full Text] [Related]
14. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
15. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
Lilleyman JS
Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
[No Abstract] [Full Text] [Related]
16.
Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
[No Abstract] [Full Text] [Related]
18. [Pharmacogenomics of acute lymphoblastic leukemia].
Ansari M; St-Onge G; Krajinovic M
Med Sci (Paris); 2007 Nov; 23(11):961-7. PubMed ID: 18021708
[TBL] [Abstract][Full Text] [Related]
19. Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy.
Ogden AK; Pollock BH; Bernstein ML; Camitta B; Buchanan GR
J Pediatr Hematol Oncol; 2002; 24(3):182-7. PubMed ID: 11990303
[TBL] [Abstract][Full Text] [Related]
20. Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.
Schieck M; Lentes J; Thomay K; Hofmann W; Behrens YL; Hagedorn M; Ebersold J; Davenport CF; Fazio G; Möricke A; Buchmann S; Alten J; Cario G; Schrappe M; Bergmann AK; Stanulla M; Steinemann D; Schlegelberger B; Cazzaniga G; Göhring G
Ann Hematol; 2020 Apr; 99(4):809-818. PubMed ID: 32078009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
